IC-QUADRO

Dosage

Children: For paediatric dosing, refer to specific local guidelines or formulary resources.

Adults: For adult dosing, refer to specific local guidelines or formulary resources.

Pregnancy

Safety during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether akko is excreted in human milk. Caution should be exercised when administered to a nursing mother.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Indications

• Infectious coryza in poultry
• Respiratory diseases caused by Avibacterium species

Dosage

Children: Refer to specific veterinary guidelines for treatment in young birds, as no standard dosing information is available.

Adults: Refer to specific veterinary guidelines for appropriate treatment protocols as no standard dosing information is available.

Mechanism of action

Avibacterium paragallinarum adheres to the epithelial cells of the respiratory tract in birds, leading to inflammation and bacterial replication. The organism's virulence is associated with its ability to evade the host immune response and establish infection, often leading to secondary bacterial infections due to mucosal damage.

Pharmacodynamics

The pathogenicity of Avibacterium is primarily due to its ability to induce local inflammation in the respiratory epithelium, which results in clinical signs typical of respiratory infections in poultry. The bacterial cell wall components may trigger immune responses, leading to further respiratory distress and susceptibility to other pathogens.

Pharmacokinetics

As a bacterial pathogen, Avibacterium does not have pharmacokinetics in the same sense as pharmaceutical drugs. However, its proliferation and survival within the host can be influenced by various factors, including the host's immune status, concurrent infections, and environmental conditions.

Pregnancy

There is limited data on the use of avibacterium during pregnancy. Consult relevant guidelines before prescribing.

Breast-feeding

Caution is advised when using avibacterium while breastfeeding due to insufficient data on its safety.

Storage

Store at room temperature, away from direct sunlight and moisture. Specific storage conditions may vary depending on the formulation.

Indications

• Hypertension
• Heart failure
• Angina pectoris
• Arrhythmias

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

Modesto primarily works as a selective beta-adrenergic antagonist, blocking the action of catecholamines on beta-adrenergic receptors in the heart. This leads to a decrease in heart rate and myocardial contractility, ultimately reducing cardiac output and lowering blood pressure. Additionally, it may have some effect on the renal system, enhancing natriuresis and reducing fluid retention.

Pharmacodynamics

The pharmacodynamic effects of Modesto include decreased heart rate (negative chronotropic effect) and decreased myocardial oxygen demand. It can also lead to vasodilation and reduced peripheral resistance, which contribute to its antihypertensive effects. The onset of action generally occurs within a few hours of administration, with peak effects seen within a day in most cases.

Pharmacokinetics

Modesto is well-absorbed following oral administration, with peak plasma concentrations typically reached within 1 to 3 hours. It undergoes extensive hepatic metabolism, primarily via cytochrome P450 enzymes. The elimination half-life varies but is generally between 3 to 6 hours, with renal excretion being a significant route of elimination for its metabolites. Steady-state concentrations are usually achieved within 3 to 5 days of regular dosing.

Pregnancy

The safety of Modesto during pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

It is not known whether Modesto is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Chronic respiratory disease in poultry
• Inflammatory processes in avian species
• Systemic infections in birds

Dosage

Children: Refer to veterinary pharmacology resources for pediatric dosing information.

Adults: Refer to clinical guidelines and veterinary pharmacology resources for specific dosing regimens.

Mechanism of action

Paragallinarum adheres to the host's epithelial cells, evading immune responses and causing localized inflammation. The bacterium produces various virulence factors, including adhesins and toxins, which facilitate colonization and tissue damage. These components disrupt normal cellular functions, promoting infection and disease progression.

Pharmacodynamics

The pharmacodynamics of treatments targeting Paragallinarum focus on inhibiting its growth and neutralizing its pathogenic effects. Antibiotics or vaccines may be used to reduce the bacterial load and mitigate the associated inflammatory response. The effectiveness of such treatments often depends on the timing of administration and the specific strain of the bacterium.

Pharmacokinetics

The pharmacokinetics of drugs used against Paragallinarum typically involve absorption after administration, distribution throughout the body, metabolism in the liver, and excretion via urine or feces. The pharmacokinetic profile can vary based on the drug class and the route of administration, influencing the duration and intensity of the therapeutic effect.

Pregnancy

Data on the use of paragallinarum during pregnancy is limited, consult a healthcare provider for guidance.

Breast-feeding

Data on the use of paragallinarum during breastfeeding is limited, consult a healthcare provider for guidance.

Storage

Store at room temperature, protect from light and moisture, and keep out of reach of children.

Indications

• Muscle strain
• Tendon strain
• Acute pain management
• Inflammation control

Dosage

Children: Refer to specific medication guidelines as dosing varies by drug used for pain management.

Adults: Refer to specific medication guidelines as dosing varies by drug used for pain management.

Mechanism of action

The mechanism of injury in strains involves the disruption of muscle fibers or tendons due to excessive tension or force. This can lead to inflammation, pain, and impaired function. Inflammatory mediators are released at the site of injury, resulting in local vasodilation, increased permeability of blood vessels, and recruitment of immune cells which contribute to the healing process.

Pharmacodynamics

The pharmacodynamics of treating strains often involve the use of analgesics and anti-inflammatory medications, which work by inhibiting cyclooxygenase (COX) enzymes, leading to decreased production of prostaglandins. This reduces pain and inflammation associated with muscle or tendon injury. Physical therapy may also play a significant role in enhancing recovery and restoring function.

Pharmacokinetics

The pharmacokinetics of medications used for strains, such as NSAIDs, vary depending on the specific drug. Generally, these agents are absorbed rapidly from the gastrointestinal tract, peak in plasma concentration within a few hours, and have a half-life that varies widely. Metabolism typically occurs in the liver, and excretion is primarily via the kidneys. Individual responses can vary based on age, weight, and overall health.

Pregnancy

Consult healthcare provider before use.

Breast-feeding

Consult healthcare provider before use.

Storage

Store in a cool, dry place, away from direct sunlight.

Pregnancy

Consult with a healthcare provider, as safety data may vary depending on the specific context and formulation.

Breast-feeding

Consult with a healthcare provider to assess risks and benefits, as data on transfer in breast milk may vary.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.